TFF Pharmaceuticals commences Phase 1 clinical trial for Voriconazole
Category: #health  By Mateen Dalal  Date: 2019-11-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

TFF Pharmaceuticals commences Phase 1 clinical trial for Voriconazole

TFF Pharmaceuticals, Inc., claims that it has initiated Voriconazole Inhalation Powder’s phase 1 clinical trial —Voriconazole’s inhaled dry powder version that is direct-to-lung and complements next-generation version. When it comes to the treatment of Invasive Pulmonary Aspergillosis (IPA), Voriconazole Inhalation Powder is regarded as the most efficacious antifungal drug.

Reportedly, the trial will start patients’ dosing this week and is slated to be undertaken at a site in Canada meant for assessing pharmacokinetic profile, tolerability and safety of Voriconazole Inhalation Powder in over 64 health subjects. The trial is anticipated to be evaluated under a Canadian CTA and US IND.

TFF Pharmaceuticals’ patented Thin Film Freezing (TFF) technology platform leverages liquid Voriconazole’s reformulation into dry powder particles with attributes perceived to be apt for inhalation delivery. For the uninitiated, the Voriconazole dry powder formulation aims at the fungal infection site in the lung and has the innate capability to be the first dry powder inhaled fungicide in the industry.

President and CEO of TFF Pharmaceuticals Glenn Mattes was all praise for TFF Pharmaceuticals that has taken a giant leap from research to product formulation to clinical trial study for Voriconazole Inhalation Powder. Mattes believes this a massive stride taken by the company and TFF technology has lived up to the expectations of innovation and viability. He went to state that TFF Pharmaceuticals will leave no stone unturned in developing new drugs with a range of commercial applications for lung condition and chronic respiratory diseases.

University of Texas Health Science Center’s Professor and Chief of Pulmonary and Critical Care, Jay Peters commented that the development of Voriconazole Inhalation Powder for the treatment of IPA is underpinned by the preclinical data produced from early animal testing with the TFF technology platform. He further asserted that the start of the first human dosing was a quantum leap towards developing an essential new drug for critically ill patients who are inflicted from IPA. Inhaled Voriconazole is believed to be instrumental in treating allergic bronchpulmonary aspergillosis (ABPA).
 

Source Credits: https://ir.tffpharma.com/news-releases/news-release-details/tff-pharmaceuticals-announces-initiation-phase-1-clinical-trial

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...